The STEP 4 trial led by Domenica Rubino showed that the effect depends on continuation: participants switched to placebo regained roughly two-thirds of their lost weight over the following year (Rubino et al., 2021)
Symptoms of hypoglycemia can range from mild (tremor, sweating, hunger, confusion) to severe (loss of consciousness, seizures, potentially fatal outcomes if prolonged or untreated), and the short but potent action profile of IGF-1 DES creates periods of high risk
Here is a breakdown of the costs for NAD administered by IV compared to administered by injection
At Week 26, the primary HbA1c endpoint was missing for 4.6% and 3.7% of patients randomized to semaglutide tablets 14 mg and empagliflozin 25 mg, respectively
Combining semaglutide with other glucose-lowering agents (insulin, sulfonylureas) is a documented hypoglycemia risk and belongs strictly under clinical supervision